After verifying that CD138+ cells can be captured in the microfluidic device, we turned to analysis of healthy donor and MM patient samples to test the hypothesis that CD138-based microfluidic cell capture can be used to isolate CPCs in MM patients and distinguish MM patient samples from healthy controls. The gene discussed is SDC1; the disease is Miyoshi myopathy.